---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-024037"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2026-07-22T11:00:18+00:00"
generated_at: "2026-07-22T11:05:29.440429+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals' subsidiary selected by DARPA for negotiation of potential award for SPARC-TMS trial

## Summary
- NRX Defense Systems received DARPA letter selecting its proposal for negotiation of a potential award for SPARC-TMS phase 2/3 trial.
- Trial combines robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.
- NRX-101 previously received FDA Breakthrough Therapy Designation; trial approved by FDA and posted on ClinicalTrials.gov (NCT07227103).
- Study sites include Harvard McLean Hospital, HOPE Therapeutics clinics, and Walter Reed National Military Medical Center.
- Selection does not constitute a final award; subject to successful negotiation of definitive terms with DARPA/DSO.

## SEC filing metadata
- accession: 0001437749-26-024037
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2026-07-22T11:00:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/0001437749-26-024037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/nrxp20260722_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-024037
- JSON: https://secwatch.observer/filing/0001437749-26-024037.json
- Plain text: https://secwatch.observer/filing/0001437749-26-024037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.